12 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 8 Phase 2, 8 Phase 3, 7 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 8 | Completed 7, Terminated 1 |
| Phase 4 | 7 | Completed 2, Recruiting 2, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Contrave: new trials by email Literature Review of Contrave trials Research Report on Contrave
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide - Obesity | Phase 4 | Active not recruiting | The Cleveland Clinic | 150 | 2025-03-01 | 2026-09-30 |
| Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity Contrave, Placebo, Diet Program - Obesity, Weight Loss | Phase 4 | Recruiting | The Royal's Institute of Mental Health Research | 40 | 2024-07-04 | 2025-07-24 |
| Weight Loss Study: Genetics and Response to Naltrexone/Bupropion Naltrexone-Bupropion Combination - Obesity | Phase 4 | Recruiting | Columbia University | 120 | 2023-06-08 | 2026-06-10 |
| Anti-obesity Pharmacotherapy and Inflammation Semaglutide, Phentermine-Topiramate combination, Phentermine - Obesity | Active not recruiting | Louisiana State University Health Sciences Center in New Orleans | 30 | 2023-06-01 | 2025-09-09 | |
| Use of Mysimba in Patients With Weight Regain After Bariatric Surgery Naltrexone-Bupropion Combination - Obesity, Morbid, Bariatric Surgery Candidate | Phase 4 | Unknown | Zuyderland Medisch Centrum | 116 | 2023-03-21 | 2023-05-30 |
| A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Semaglutide, Orlistat, Phentermine/Topiramate - Obesity | Phase 4 | Completed | Novo Nordisk A/S | 500 | 2023-01-19 | 2026-01-14 |
| Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 24 | 2022-06-10 | 2026-08-26 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo - Loss-of-control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 92 | 2021-06-29 | 2026-08-26 |
| Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study Contrave, Behavioral Weight Loss - Breast Cancer, Overweight or Obesity | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 53 | 2021-02-08 | 2025-03-06 |
| Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo - Binge-Eating Disorder | Phase 2 / Phase 3 | Completed | Yale University | 89 | 2018-04-17 | 2024-04-03 |
| Individualized Obesity Pharmacotherapy Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion - Obesity | Phase 3 | Completed | Mayo Clinic | 193 | 2017-12-11 | 2023-07-18 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment) - Binge-Eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 31 | 2017-09-05 | 2024-02-01 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy NB medication (Naltrexone Bupropion combination), Placebo - Binge-Eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 68 | 2017-08-28 | 2024-02-02 |
| Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic Intervention Control, Counselling, Contrave - Obesity | Phase 4 | Completed | University of Nebraska | 86 | 2017-07-01 | 2024-08-29 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo - Binge-eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 136 | 2017-02-27 | 2023-03-08 |
| Naltrexone/Bupropion Cardiovascular Outcomes Study Naltrexone HCl/Bupropion HCl ER, Placebo - Obesity, Cardiovascular Diseases | Phase 4 | Terminated | Orexigen Therapeutics, Inc | 67 | 2016-01-01 | 2017-02-27 |
| Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets) - Healthy | Phase 1 | Completed | Orexigen Therapeutics, Inc | 80 | 2014-09-01 | 2014-12-11 |
| Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) NB32, PBO, Weight Management Program - Obesity, Overweight | Phase 3 | Terminated | Orexigen Therapeutics, Inc | 8910 | 2012-06-01 | 2017-02-27 |
| A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent NB32, Ancillary therapy - Nicotine Dependence, Overweight | Phase 2 | Completed | Orexigen Therapeutics, Inc | 30 | 2007-10-01 | 2012-11-02 |
Obesity (17) · Overweight (6) · Binge-Eating Disorder (4) · Cardiovascular Diseases (2) · Weight Loss (2) · Body Weight (1) · Breast Neoplasms (1) · Depression (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Dyslipidemias (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Heart Diseases (1) · Inflammation (1)
Yale University (6) · Orexigen Therapeutics, Inc (4) · Columbia University (1) · Louisiana State University Health Sciences Center in New Orleans (1) · Mayo Clinic (1) · Novo Nordisk A/S (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · The Cleveland Clinic (1) · The Royal's Institute of Mental Health Research (1) · University of Nebraska (1) · Zuyderland Medisch Centrum (1)
United States (17) · Canada (1) · Netherlands (1)
Carlos M Grilo, PhD (3) · Andres J Acosta (1) · Bartolome Burguera, M.D (1) · Carlos Grilo, PhD (1) · Jan Willem Greve, MD, PhD, professor (1) · Jennifer Sheng (1) · Judith Korner, MD,PhD (1) · Maria D Sanchez-Pino, Ph.D. (1) · Nader Oskooilar, M.D., Ph.D. (1) · Pierre Blier, M.D., Ph.D (1) · Sherry McKee, PhD (1) · Trina M Aguirre (1)
PMID 26954408, PMID 33389719, PMID 33759389, PMID 36285406
R01DK049587 (3), R01DK126637 (2), R01DK112771 (1), R01DK132527 (1), U24DK132740 (1)